(Q47243589)

English

Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C: a randomized phase II study

scientific article published on 17 July 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/22473713

Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C: a randomized phase II study (English)

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/22473713

1 reference

based on heuristic

inferred from title

chronic hepatitis C

1 reference

based on heuristic

inferred from title

pegylated interferon

1 reference

based on heuristic

inferred from title

chronic hepatitis

1 reference

based on heuristic

inferred from title

Patrick Marcellin

6

object named as

Patrick Marcellin

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/22473713

1

object named as

Michael P Manns

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/22473713

author name string

Edward Gane

2

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/22473713

Maribel Rodriguez-Torres

3

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/22473713

Albrecht Stoehr

4

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/22473713

Chau-Ting Yeh

5

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/22473713

Richard T Wiedmann

7

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/22473713

Peggy M Hwang

8

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/22473713

Luzelena Caro

9

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/22473713

Richard J O Barnard

10

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/22473713

Andrew W Lee

11

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/22473713

MK-7009 Protocol 007 Study Group

12

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/22473713

language of work or name

0 references

publication date

17 July 2012

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/22473713

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/22473713

56

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/22473713

3

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/22473713

884-893

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/22473713

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.25743

21 January 2018

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.25743

21 January 2018

Boceprevir for untreated chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.25743

21 January 2018

Boceprevir for previously treated chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.25743

21 January 2018

Telaprevir for previously untreated chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.25743

21 January 2018

Telaprevir for previously treated chronic HCV infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.25743

21 January 2018

Telaprevir for retreatment of HCV infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.25743

21 January 2018

Response-guided telaprevir combination treatment for hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.25743

21 January 2018

Hepatitis in 2010: the dawn of a new era in HCV therapy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.25743

21 January 2018

Regulation of Interferon Regulatory Factor-3 by the Hepatitis C Virus Serine Protease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.25743

21 January 2018

Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF

1 reference

https://api.crossref.org/works/10.1002%2FHEP.25743

21 January 2018

Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.25743

21 January 2018

Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients

1 reference

https://api.crossref.org/works/10.1002%2FHEP.25743

21 January 2018

Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.25743

21 January 2018

Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.25743

21 January 2018

MK-7009, a Potent and Selective Inhibitor of Hepatitis C Virus NS3/4A Protease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.25743

21 January 2018

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

1 reference

https://api.crossref.org/works/10.1002%2FHEP.25743

21 January 2018

Hepatitis C virus resistance to protease inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FHEP.25743

21 January 2018

In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.25743

21 January 2018

In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.25743

21 January 2018

GT-1a or GT-1b Subtype-Specific Resistance Profiles for Hepatitis C Virus Inhibitors Telaprevir and HCV-796

1 reference

https://api.crossref.org/works/10.1002%2FHEP.25743

21 January 2018

Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report

1 reference

https://api.crossref.org/works/10.1002%2FHEP.25743

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/HEP.25743

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/22473713

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/22473713

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47243589&oldid=2147726734"